Table 3

 Risk of colorectal cancer (CRC) and type and duration of inflammatory bowel disease (IBD)

CharacteristicCases (n = 100)Controls (n = 600)Crude OR (95% CI)
*Type of IBD was not specified by the general practitioner for a small number of patients.
†Based on the time period between the date of the first IBD recording or 5-aminosalicylate prescribing and the index date.
UC, ulcerative colitis; CD, Crohn’s disease; OR (95% CI), odds ratio (95% confidence interval).
Type of IBD*
    UC763992.86 (1.22–6.72)
Duration of UC†
    0–2 y1377Reference
    2–10 y231771.08 (0.52–2.27)
    >10 y401452.12 (1.07–4.19)
Duration of CD†
    0–2 y231Reference
    2–10 y5591.56 (0.49–4.93)
    >10 y8273.16 (1.15–8.68)